STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[Form 4/A] PERRIGO COMPANY PLC Amended Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4/A
Rhea-AI Filing Summary

Perrigo Company plc (PRGO) Form 4/A corrects an earlier filing to show that on 08/18/2025 the reporting person, Geoffrey M. Parker, had 4,375 ordinary shares acquired at a price of $22.9708, and those shares were acquired indirectly by the Geoffrey M. Parker Roth IRA rather than directly. After this transaction the Roth IRA held 9,875 shares. The filing also lists other holdings: 28,912 ordinary shares disposed (as reported) and 25,879 ordinary shares held indirectly via a revocable trust in which Geoffrey and Jill Parker are trustees. The amendment states the only change from the original Form 4 is correcting the manner of acquisition to reflect the IRA ownership. The form is signed by an attorney-in-fact for Mr. Parker on 08/19/2025.

Positive
  • Correction filed to accurately attribute the 4,375-share purchase to the Geoffrey M. Parker Roth IRA, demonstrating regulatory compliance.
  • Transaction details disclosed: 4,375 shares purchased at $22.9708 on 08/18/2025, with Roth IRA holding 9,875 shares post-transaction.
  • Additional holdings disclosed: revocable trust holds 25,879 shares, improving transparency of indirect ownership.
Negative
  • Initial misreporting on the Original Form 4 required an amendment to correct the manner of acquisition, indicating a reporting error.

Insights

TL;DR: Amendment corrects beneficial ownership attribution to an IRA; no change to number of shares bought or price.

The amendment is narrowly focused and transparent: it corrects the reporting of the purchaser's capacity from direct ownership to indirect ownership via a Roth IRA. This is an administrative correction that does not alter the economic exposure reported (4,375 shares at $22.9708) nor the aggregate beneficial positions disclosed. From a governance perspective, timely correction maintains compliance with Section 16 reporting obligations and reduces technical risk of misfiling penalties.

TL;DR: Filing fixes attribution error; disclosure now clarifies ownership by IRA and revocable trust.

The Form 4/A clarifies that the acquired shares were held by the reporting person's Roth IRA, and it specifies existing indirect holdings via a revocable trust. The amendment and the explanatory footnotes improve clarity for investors and regulators about who exercises control and potential trading restrictions. No new transactions, prices, or quantities beyond the corrected attribution are introduced.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Parker Geoffrey M.

(Last) (First) (Middle)
C/O PERRIGO COMPANY PLC
515 EASTERN AVENUE

(Street)
ALLEGAN MI 49010

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PERRIGO Co plc [ PRGO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
08/19/2025
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 08/18/2025 P 4,375 A $22.9708 9,875 I IRA(1)(2)
Ordinary Shares 28,912 D
Ordinary Shares 25,879 I Revocable Trust(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Geoffrey M. Parker Roth IRA.
2. This Form 4/A is being filed to correct the manner in which the Reporting Person purchased shares of Perrigo Company plc. The original Form 4, filed on August 19, 2025 (the "Original Form 4") reported the purchase of 4,375 shares by Mr. Parker directly, where such shares were in fact acquired indirectly by the Geoffrey M. Parker Roth IRA, as reflected in this Form 4/A. Other than as described in this footnote, there are no other changes from the Original Form 4.
3. Revocable trust in which Geoffrey Parker and Jill Parker are the trustees.
Remarks:
/s/ Diana Witt, attorney-in-fact for Mr. Geoffrey Parker 08/19/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Geoffrey M. Parker report on the Form 4/A for PRGO?

The filing reports a purchase of 4,375 ordinary shares of Perrigo (PRGO) on 08/18/2025 at a price of $22.9708.

Why was the Form 4 amended (Form 4/A)?

The amendment corrects the manner of acquisition, stating the 4,375 shares were acquired indirectly by the Geoffrey M. Parker Roth IRA rather than directly by Mr. Parker.

How many PRGO shares does the Geoffrey M. Parker Roth IRA hold after the transaction?

The filing shows the Roth IRA held 9,875 shares following the reported transaction.

Does the filing disclose other holdings by Mr. Parker?

Yes; the filing lists 25,879 ordinary shares held indirectly via a revocable trust (Geoffrey and Jill Parker are trustees) and a reported 28,912 shares line marked as disposed in the table.

Who signed the amended Form 4 and when?

The form is signed by Diana Witt, attorney-in-fact for Mr. Geoffrey Parker on 08/19/2025.
Perrigo Co Plc

NYSE:PRGO

PRGO Rankings

PRGO Latest News

PRGO Latest SEC Filings

PRGO Stock Data

2.78B
136.97M
0.41%
105.88%
5.38%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
Ireland
DUBLIN 2